Core Viewpoint - The announcement highlights the long-term efficacy and safety of pimicotinib in treating TGCT patients, reinforcing its potential for long-term application in suitable patients [1] Group 1: Company Information - The subsidiary Shanghai Heyu Biopharmaceutical Technology Co., Ltd. presented data at the CTOS 2025 conference regarding the global Phase III MANEUVER study of pimicotinib for TGCT patients [1] - The long-term analysis indicates that continuous treatment with pimicotinib leads to sustained improvements in tumor response and patient-reported outcomes, including pain and function [1] - The study emphasizes that the treatment maintains an acceptable safety profile, supporting the long-term use of pimicotinib in appropriate patients [1]
和誉-B：和誉医药于CTOS 2025年会展示匹米替尼临床III期 MANEUVER研究长期疗效和安全性数据